Ypsomed Holding AG
SIX:YPSN

Watchlist Manager
Ypsomed Holding AG Logo
Ypsomed Holding AG
SIX:YPSN
Watchlist
Price: 342.5 CHF -0.15% Market Closed
Market Cap: 4.7B CHF
Have any thoughts about
Ypsomed Holding AG?
Write Note

Operating Margin
Ypsomed Holding AG

14.1%
Current
10%
Average
4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
14.1%
=
Operating Profit
86.8m
/
Revenue
617.1m

Operating Margin Across Competitors

Country CH
Market Cap 4.7B CHF
Operating Margin
14%
Country JP
Market Cap 7T JPY
Operating Margin
28%
Country CH
Market Cap 38.2B CHF
Operating Margin
13%
Country DK
Market Cap 177.1B DKK
Operating Margin
27%
Country US
Market Cap 16.3B USD
Operating Margin
17%
Country KR
Market Cap 10.3T KRW
Operating Margin
-245%
Country CN
Market Cap 51B CNY
Operating Margin
45%
Country US
Market Cap 6.7B USD
Operating Margin
32%
Country CA
Market Cap 6.3B USD
Operating Margin
4%
Country UK
Market Cap 4.6B GBP
Operating Margin
13%
Country US
Market Cap 5.6B USD
Operating Margin
12%
No Stocks Found

Ypsomed Holding AG
Glance View

Market Cap
4.7B CHF
Industry
Health Care

Nestled amid the pioneering spirit of the Swiss medical technology landscape, Ypsomed Holding AG emerges as a quintessential player, carving a niche in the diabetes care and injection systems domains. The company’s journey begins in the Ypsomed headquarters in Burgdorf, Switzerland, where innovation meets precision engineering. Ypsomed's focus largely revolves around its development, production, and distribution of self-injection devices and solutions. This Swiss dynamo engages in crafting state-of-the-art insulin pumps, pen injectors, and smart add-on devices that empower users with diabetes to manage their conditions effectively. It combines clinical expertise with intuitive design, ensuring that their diverse clientele—from patients to medical professionals—receive products that blend seamlessly into everyday life. Not resting on insulin delivery alone, Ypsomed also establishes itself in the world of contract manufacturing, catering to global pharmaceutical and biotech companies with their platform technology and customized solutions. Economically vibrant, Ypsomed’s revenue streams are woven intricately from an array of channels. A significant proportion stems from direct sales of its proprietary diabetes care products under their acclaimed mylife™ brand. Here, it garners a loyal customer base through innovations like the YpsoPump® system, effectively capitalizing on the growing demand for user-friendly diabetes management tools. Additionally, Ypsomed capitalizes on partnerships with major healthcare multinationals by providing contract manufacturing services and licensing technologies, expanding its global footprint while tapping into broader markets. As a strategic player, the company continuously invests in research and development to refine its offerings and maintain a competitive edge in the burgeoning medical device market. Through this dynamic blend of cutting-edge technology and strategic alliances, Ypsomed illustrates a sophisticated business model that not only sustains its profitability but furthers its mission to improve the lives of those in need of reliable, advanced diabetes care solutions.

YPSN Intrinsic Value
313.25 CHF
Overvaluation 9%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
14.1%
=
Operating Profit
86.8m
/
Revenue
617.1m
What is the Operating Margin of Ypsomed Holding AG?

Based on Ypsomed Holding AG's most recent financial statements, the company has Operating Margin of 14.1%.